Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study

Auckland City Hospital /ID# 200945, Grafton

Inselspital, Universitätsspital Bern /ID# 155716, Bern

The Royal Melbourne Hospital /ID# 155727, Parkville

Waikato Hospital /ID# 155728, Hamilton

Royal Brisbane and Women's Hospital /ID# 200944, Herston

Dunedin Hospital /ID# 155591, Otago

University of Buffalo /ID# 155721, Buffalo

Asklepios Klinik St. Georg /ID# 155733, Hamburg

Digestive Disease Associates - Baltimore /ID# 155713, Baltimore

Hospital Universitario Puerta de Hierro, Majadahonda /ID# 155734, Majadahonda

Carolinas Center For Liver Dis /ID# 155731, Statesville

Digestive Health Specialists of the Southeast /ID# 155719, Dothan

Gastro One /ID# 155729, Germantown

Zentru fur HIV und Heaptogastroenterologie /ID# 155592, Düsseldorf

Henry Ford Health System /ID# 155720, Detroit

TX Liver Inst, Americ Res Corp /ID# 157881, San Antonio

Ruane Clinical Research Group /ID# 155714, Los Angeles

Beijing Di Tan Hospital, Capital Medical University /ID# 218496, Beijing

Mengchao Hepatobiliary Hospital of Fujian Medical University /ID# 218495, Fuzhou

The First Hospital Affiliated to AMU (Southwest Hospital) /ID# 218494, Chongqing

Medical Company Hepatolog /ID# 214314, Samara

West China Hospital, Sichuan University /ID# 217613, Chengdu

University of Calgary /ID# 155726, Calgary

Samsung Medical Center /ID# 214844, Seoul

Duplicate_Karolinska Univ Sjukhuset /ID# 155735, Solna

Duplicate_Imperial College Healthcare NHS Trust /ID# 155718, London